Literature DB >> 10390252

Cost of chickenpox in Canada: part I. Cost of uncomplicated cases.

B Law1, C Fitzsimon, L Ford-Jones, N MacDonald, P Déry, W Vaudry, E Mills, S Halperin, A Michaliszyn, M Rivière.   

Abstract

OBJECTIVE: The purpose of this study was to assess the direct medical costs and productivity losses associated with uncomplicated chickenpox (no hospitalization) in Canada.
METHODS: A total of 179 otherwise healthy 1- to 9-year-old children with active chickenpox were recruited from schools, day care centers, and physician offices in 5 provinces. Direct medical (physician contacts, medication, and diagnostic tests) and nonmedical (personal expenses including child care) resources expended during the illness were determined by caregiver interview. Productivity losses attributable to the disease were determined by assessing caregiver time lost from work and daily activities. Unit costs for all resources were obtained from sources in 2 provinces, and per-patient treatment costs were determined from the patient, Ministry of Health, and societal perspectives.
RESULTS: From a societal perspective, the per-case cost for children from 1 to 4 years of age and from 5 to 9 years of age was $370.2 and $236.5, respectively. Direct medical costs accounted for 10% of the total costs in both groups. The largest cost driver in patient care was caregiver productivity losses, which amounted to $316.5 in the younger age group and to $182.7 in the older age group. Based on an estimated yearly incidence of 344 656 cases of uncomplicated chickenpox in Canada, the total annual societal burden of the disease can be estimated at $109.2 million, with a cost to the Ministry of Health of $11.2 million.
CONCLUSION: Chickenpox is one of the last common childhood diseases prevalent in Canada, and the uncomplicated disease, despite its rather benign course, imparts a large annual economic burden.

Entities:  

Mesh:

Year:  1999        PMID: 10390252     DOI: 10.1542/peds.104.1.1

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Varicella control and vaccine coverage: issues and challenges.

Authors:  Tamara Wallington; Erica Weir
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

Review 2.  25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview.

Authors:  M Takahashi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Chickenpox vaccination, not chickenpox, should be routine for Canadian children.

Authors:  B J Law
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

4.  Varicella vaccination in England and Wales: cost-utility analysis.

Authors:  M Brisson; W J Edmunds
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 5.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Canada's first universal varicella immunization program: Lessons from Prince Edward Island.

Authors:  Lamont Sweet; Peggy Gallant; Marie Morris; Scott A Halperin
Journal:  Can J Infect Dis       Date:  2003-01

7.  Varicella vaccine for children.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-07       Impact factor: 2.253

8.  Towards universal childhood immunization against chickenpox?

Authors:  B J Law
Journal:  Paediatr Child Health       Date:  2000-07       Impact factor: 2.253

9.  Three-year follow-up of protection rates in children given varicella vaccine.

Authors:  David W Scheifele; Scott A Halperin; Francisco Diaz-Mitoma
Journal:  Can J Infect Dis       Date:  2002-11

10.  Burden of chickenpox on families: A study in Quebec.

Authors:  P De Wals; M Blackburn; M Guay; G Bravo; D Blanchette; M Douville-Fradet
Journal:  Can J Infect Dis       Date:  2001-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.